Αποτελέσματα Αναζήτησης
ORTHO EVRA ® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin (NGMN) and 0.75 mg ethinyl estradiol (EE). Systemic...
ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm 2 .It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE),and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.
Posology and method of administration. To achieve maximum contraceptive effectiveness, patients must be advised to use EVRA exactly as directed. For initiation instructions see ‘How to start EVRA’ below. Only one transdermal patch is to be worn at a time.
The EVRA® (norelgestromin and ethinyl estradiol) transdermal system is indicated for the prevention of pregnancy. The pharmacokinetic profile for the EVRA® transdermal system is different from that of an oral contraceptive. The clinical relevance of the differences in PK profiles between
23 Απρ 2024 · Ortho Evra Dosage. Generic name: norelgestromin 150ug in 1d, ethinyl estradiol 35ug in 1d. Dosage form: patch, extended release. Drug class: Contraceptives. Medically reviewed by Drugs.com. Last updated on Apr 23, 2024. To achieve maximum contraceptive effectiveness, ORTHO EVRA must be used exactly as directed.
Overview. This is a summary of the European public assessment report (EPAR) for Evra. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Evra.
A transdermal contraceptive patch (Ortho EvraTM/EvraTM) has been developed by The R.W. Johnson Pharmaceutical Research Insti-tute. Pharmacokinetic studies have shown that the contraceptive patch delivers norelgestromin and ethinyl estradiol (EE) to the systemic cir-culation (1–6).
